Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Bevacizumab in Advanced Breast Cancer
NCT00623233Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2008
- Primary completion
- Jan 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, bevacizumab in breast cancer, sponsored by Eli Lilly and Company. Started Mar 2008; status: completed.
02
Drugs
gemcitabinebevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00623233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00623233.